Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryOct282015	Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies Read All »	View HTML Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions 20.8 KB
Toggle SummaryDec132021	Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting 5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 10 of 11 Patients Read All »	View HTML
Toggle SummaryJul312014	Fate Therapeutics Secures Up to $20 Million in Debt Financing Strengthened Cash Position Expected to Fund Company Through 2015 Read All »	View HTML Fate Therapeutics Secures Up to $20 Million in Debt Financing 15.3 KB
Toggle SummaryApr102014	Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. Read All »	View HTML Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics 14.6 KB
Toggle SummaryDec082011	Fate Therapeutics Secures Foundational Patent for IPS Cell Programming U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics secures foundational patent for IPS cell programming 136.2 KB
Toggle SummaryDec032018	Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA SAN DIEGO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company Read All »	View HTML
Toggle SummaryMar122015	Fate Therapeutics Reports Year-End 2014 Financial Results Favorable Phase 2 Interim Data From Ongoing PUMA Study of PROHEMA® in Adult Hematologic Malignancies Reported in December 2014 PROHEMA Clinical Data in Pediatric Hematologic Malignancies and Rare Genetic Disorders Expected in 2015 IND for Programmed Mobilized Peripheral Blood Candidate Using Read All »	View HTML Fate Therapeutics Reports Year-End 2014 Financial Results 34.8 KB
Toggle SummaryNov082023	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma ; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors Read All »	View HTML
Toggle SummaryNov032022	Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback Received from FDA under FT516 RMAT Designation for Derivation of Clonal Engineered Master iPSC Bank Read All »	View HTML
Toggle SummaryNov042021	Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of CRS and No Events Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.